

Structural Neuroimaging Studies in Major Depressive Disorder

Meta-analysis and Comparison With Bipolar Disorder

Matthew J. Kempton, MSc, PhD; Zainab Salvador, BSc; Marcus R. Munafò, MSc, PhD; John R. Geddes, MD, FRCPsych; Andrew Simmons, MSc, PhD; Sophia Frangou, MD, MSc, PhD, MRCPsych; Steven C. R. Williams, BSc, PhD

Context: Although differences in clinical characteristics exist between major depressive disorder (MDD) and bipolar disorder (BD), consistent structural brain abnormalities that distinguish the disorders have not been identified.

Objectives: To investigate structural brain changes in MDD using meta-analysis of primary studies; assess the effects of medication, demographic, and clinical variables; and compare the findings with those of a meta-analysis of studies on BD.

Data Sources: The MEDLINE, EMBASE, and PsycINFO databases were searched for studies from January 1, 1980, to February 2, 2010.

Study Selection: Two hundred twenty-five studies that used magnetic resonance imaging or x-ray computed tomography to compare brain structure in patients with MDD with that of controls were included in an online database, and 143 that measured common brain structures were selected for meta-analysis.

Data Extraction: Twenty-five variables, including demographic and clinical data, were extracted from each study, when available. For the meta-analysis, mean structure size and standard deviation were extracted for continuous vari-

ables, and the proportion of patients and controls with an abnormality in brain structure was extracted for categorical variables.

Data Synthesis: Compared with the structure of a healthy brain, MDD was associated with lateral ventricle enlargement; larger cerebrospinal fluid volume; and smaller volumes of the basal ganglia, thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus. Patients during depressive episodes had significantly smaller hippocampal volume than patients during remission. Compared with BD patients, those with MDD had reduced rates of deep white matter hyperintensities, increased corpus callosum cross-sectional area, and smaller hippocampus and basal ganglia. Both disorders were associated with increased lateral ventricle volume and increased rates of subcortical gray matter hyperintensities compared with healthy controls.

Conclusions: The meta-analyses revealed structural brain abnormalities in MDD that are distinct from those observed in BD. These findings may aid investigators attempting to discriminate mood disorders using structural magnetic resonance imaging data.

Arch Gen Psychiatry. 2011;68(7):675-690

EPIDEMIOLOGIC AND TREATMENT studies have confirmed differences in clinical characteristics between major depressive disorder (MDD) and bipolar disorder (BD). Major depressive disorder, compared to BD, has a higher lifetime prevalence (16% vs 2%),^{1,2} has an older median age at onset (32 vs 25 years),³ and is associated with a lower number of depressive episodes.⁴ Antidepressants are the most commonly prescribed medication for MDD⁵; mood stabilizers, such as lithium, are the most frequently prescribed treatment for BD.⁶ However, despite these differences, consistent biomarkers distinguishing the disorders have been elusive.

It is not clear whether changes in brain structure differentiate MDD from BD or

whether common abnormalities are present in both disorders. Reviews^{7,8} of imaging studies have attempted to identify structural differences specific to each disorder in a qualitative fashion. In addition, meta-analyses, which quantitatively summarize research findings, have revealed evidence of structural abnormalities in patients with BD⁹⁻¹¹ and MDD¹²⁻¹⁶ compared with healthy individuals. However, to our knowledge, meta-analytical methods have not been used to establish whether the identified abnormalities distinguish the disorders.

In the present study, we conducted a comprehensive meta-analysis of studies on brain structural changes in patients with MDD compared with controls and examined the specificity of these abnormalities by comparing the findings with those

Author Affiliations are listed at the end of this article.

found in patients with BD. In the meta-analysis of MDD imaging studies, we increased both the number of included publications and brain regions by a factor of 2 compared with the largest previous meta-analysis.¹³ Using data from a meta-analysis of studies on BD,⁹ we made direct statistical comparisons between structural measures from each disorder while attempting to control for differences in study characteristics such as scanning parameters and patient demographics. Previous meta-analyses^{12,13} of studies on patients with MDD most consistently report hippocampal volumetric reduction; we applied meta-regression techniques to investigate the effect of clinical variables on hippocampal volume. Finally, we provide an online database of 225 MDD structural imaging studies, listing 25 variables from each study, when available (<http://www.depressiondatabase.org>). The database is presented as an open-access wiki,¹⁷ enabling other researchers to add studies.

METHODS

The study was divided into 3 parts: (1) the construction of a database of 225 studies investigating structural abnormalities in MDD, (2) a meta-analysis comparing patients with MDD with controls from a subgroup of 143 studies, and (3) a statistical comparison of structural abnormalities between patients with MDD and those with BD.

DATABASE OF IMAGING STUDIES IN MDD

The inclusion criteria for the database required peer-reviewed studies that measured brain structure using x-ray computed tomography (CT) or magnetic resonance imaging (MRI) in patients with MDD and a control group. The MEDLINE, EMBASE, and PsycINFO databases were searched from January 1, 1980, to February 2, 2010, using a combination of relevant expanded subject headings and free-text searches; detailed search terms are given in our wiki database. A total of 3960 records of unique publications were initially examined; we excluded case studies, reviews, studies that had not used standard diagnostic criteria, studies that combined MDD with BD patients in a single group, duplicate publications, and investigations using voxel-based morphometry (VBM) because the results of these studies cannot be included in a traditional meta-analysis. We did not include epidemiologic studies that diagnosed depression based on cutoffs of rating scales or considered antidepressant use a proxy for MDD diagnosis because the agreement between these measures and standard diagnostic criteria is questionable.¹⁸ Two hundred twenty-five publications fulfilled the inclusion criteria and were included in the database.

DATA RECORDED IN THE DATABASE

The following data were recorded from each study when available: number of MDD patients and controls, mean age, number of males and females in the patient and control groups, and the diagnostic classification system used. Mean age of the patient at onset of the disease and mean Hamilton Scale for Depression (HAM-D)¹⁹ score were also recorded. The HAM-D scale was chosen over other depression rating scales because it is the most commonly reported. For current medication, we recorded the number of patients who were described as *drug free* (not necessarily medication naive), as well as the number using mood stabilizers, antipsychotics, and antidepressants, including the class of antidepressant (selective serotonin reuptake in-

hibitor, tricyclic, monoamine oxidase inhibitor, or other). Information on current medication use was extracted from the publications directly; because data regarding prior exposure to medication were rarely presented, this information was not systematically collected. For each study, we recorded all brain structures or abnormalities measured, whether the measurement was MRI or CT based, slice thickness, and field strength of the MRI scanner.

The majority of variables in the database were not normally distributed; therefore, correlations were assessed using Spearman rank correlation (SPSS 15.0; SPSS Inc, Chicago, Illinois).

MDD META-ANALYSIS

Identification of Brain Regions/Abnormalities to Be Included in the Meta-analysis

To ensure no bias in selecting brain regions/abnormalities for the meta-analysis, we recorded every structure or abnormality investigated in the 225 studies. As with previous meta-analyses, exact anatomic definitions of individual structures varied across studies. For a given structure, some studies reported left and right measurements separately, and other studies reported the combined measurement. For studies that reported measures for the left and right volumes but not the total, we determined the mean and standard deviation for the total volume, using a reported method¹³ that requires an estimate of the correlation coefficient between the left and right volumes. This coefficient was set as 0.8, although it was varied in the sensitivity analysis (described in the “Sensitivity Analysis” subsection of the “Methods” section). To ensure that the meta-analysis was sufficiently powered, brain regions were included if there were 3 or more independent studies that reported a mean and SD in both the control and patient groups (continuous measures), and abnormalities were included if there were 3 or more independent studies that reported the number of patients and controls with the abnormality (categorical measure). From the 225 studies in the database, there were a total of 324 different brain regions examined; however, only 63 regions were examined by 3 or more studies, and these were entered in the meta-analysis. The total number of studies included in the meta-analysis was 143; many studies in the database did not examine 1 or more of the 63 identified regions. The studies in the meta-analysis included 9 publications that used CT measures of total lateral ventricle volume (analyzed as a subgroup), and all other brain structures were examined using MRI.

Combining Study Estimates

For continuous outcome measures, Hedges *g* was used, which is the Cohen effect size with a correction for bias from small sample sizes.²⁰ The percentage difference effect size is also provided to aid biological interpretation of the data.²¹ The majority of studies report absolute volume measures; however, some report volumes as ratios of the entire brain or cross-sectional area measures. All such measurements have been included in the meta-analysis; however, because combining measures may increase heterogeneity, an additional analysis was carried out with volume measures only (see “Sensitivity Analysis” subsection of the “Methods” section). For categorical outcome measures, the odds ratio was used. Outcome measures were recorded from each study and were independently checked to ensure accuracy. For a given brain structure, if 2 or more studies by the same research group reported similar patient or control demographics, we contacted the authors of those studies to determine whether there was overlap in the sample and, if

this was the case, included only the largest relevant study. A total of 150 measures from 52 studies were excluded for this reason. A meta-analysis for each brain structure was performed (using the `metan` command in Stata 9.2, 2006; Stata-Corp LP, College Station, Texas). Outcome measures were combined using a random-effects inverse-weighted variance model.²² Because the meta-analyses examined a large number of regions and are susceptible to type I errors, results that survive Bonferroni correction for multiple comparisons (corrected for 63 regions, $P < .0008$) are indicated.

Combining Patient Subgroups

A minority of imaging studies presented measures from subgroups of patients. For these studies, we entered the subgroups in the meta-analysis as if they were separate studies and, in each case, the number of individuals in the control group was considered the sample size of the control group divided by the number of patient subgroups. This method has been used in a previous meta-analysis.⁹ If studies reported on males and females separately, we entered the results as if they were from 2 separate studies, a technique adopted by another previous meta-analysis.²³

Assessing Between-Study Heterogeneity

To test for between-study heterogeneity, the Cochran Q test statistic was calculated.²⁴ The I^2 statistic, which is equal to the percentage of total variation across studies as the result of heterogeneity, was also calculated to aid interpretability of between-study heterogeneity.²⁵

Small-Study Bias

The effect of small-study bias (which may include publication bias) was investigated for regions in which the pooled effect size revealed a significant group difference between MDD patients and controls and when at least 5 studies were included in the meta-analysis to ensure that the test was sufficiently powered. Small-study bias was assessed using the Egger regression test.²⁶

Effect of Clinical Variables on Hippocampal Volume

The number of brain regions and clinical variables included in the database allows a potentially high number of correlations to be examined, which may lead to type I errors. Thus, the analysis was limited to the effect of clinical variables on total hippocampal volume. We selected this region because of the robust evidence of volumetric reduction in MDD^{12,13} and because many studies have measured this structure, ensuring adequate statistical power. A random effects meta-regression was implemented (`metareg` command in Stata 9.2) to examine age at onset, HAM-D score, percentage of patients using antidepressants, number of depressive episodes, and patient age. In addition, we combined studies that directly compared the same MDD subgroups (eg, depressed vs remitted patients) in a supplementary meta-analysis. Finally, we determined whether the reduction in hippocampal volume remained when the meta-analysis was restricted to the following MDD patient groups: no comorbid anxiety disorders, no history of alcohol/substance abuse or dependence, first episode, adolescents, adults, and elderly patients.

Sensitivity Analysis

To test how robust the results were to variations in the meta-analysis method, the effect of the following was examined: (1)

percentage difference in the patient and control mean volumes as an outcome measure for continuous data (calculation of this effect size and the effect size variance has been described in more detail in previous meta-analytical studies^{21,23}); (2) excluding studies that reported continuous data as areas, lengths, or ratios rather than absolute volume; and (3) setting the correlation coefficient between the left and right regional volumes as 0.1, 0.5, and 1.

COMPARISON WITH BD

Stratified Meta-analysis

Two meta-analytical approaches may be taken to examine differences between MDD and BD: (1) meta-analysis of studies directly comparing the same brain structure in patients with MDD vs those with BD or (2) indirect analysis comparing the pooled effect size from studies comparing MDD patients vs controls with that from studies comparing BD patients vs controls. We adopted the second approach, which has the advantage of including more studies and brain structures because there are very few direct comparisons. Thus, to compare the results from the MDD meta-analysis with those of a previous meta-analysis of BD studies,⁹ we combined the effect sizes from BD patients vs controls with MDD patients vs controls (effectively, a meta-analysis of studies on patients with affective disorder) and performed a stratified meta-analysis using a z test to compare across the 2 disorders. To match the method exactly, the BD meta-analysis was reanalyzed, using the technique of combining left and right brain structural measures adopted in the present MDD meta-analysis. To reduce the number of comparisons, we focused on brain regions that were significantly different from those of controls (before Bonferroni correction) in either the MDD or BD meta-analysis.

Verifying Diagnostic Differences

We adopted a 2-stage process to ensure that significant differences between the groups that were identified in the stratified meta-analysis were not the result of variations in patient demographics or scanning parameters rather than MDD or BD diagnosis. First, for each brain structure, we examined whether the following summary variables were significantly different between MDD and BD studies, using an independent-samples t test: percentage of patients who were female, medication free, using antidepressants, using neuroleptics, and using mood stabilizers; mean patient age; scanner magnetic field strength; and slice thickness. Second, when a significant difference was identified between BD and MDD studies for those variables, a meta-regression was performed separately in MDD and BD studies to examine the effect of the variable on the given brain structure.

RESULTS

Demographic and clinical data from the database are reported, followed by results from the MDD meta-analyses and comparison with the BD meta-analysis.

DATABASE OF IMAGING STUDIES IN MDD

Details from 225 studies that included a total of 9533 patients with MDD and 8846 controls were entered into the database. **Table 1** summarizes the variables recorded.

Table 1. Patient and Control Demographic and Clinical Data Recorded in the Database

Variable	No. of Studies Reporting Variable	Mean (SD) Between Studies	Pooled No. of Participants in Database
No. of patients	225	42.4 (39.1)	9533
No. of controls	225	39.3 (29.2)	8846
Age, y			
Patient, mean	182	52.2 (17.9)	
Patient, SD	176	9.1 (3.9)	
Control, mean	205	50.6 (18.3)	
Control, SD	196	8.7 (3.8)	
Age at onset	93	37.5 (15.2)	
HAM-D score ^a	90	20.3 (5.8)	
		Participants in Each Study, Mean (SD), %	
Female patients	207	65.4 (17.6)	6028
Female controls	207	61.2 (17.2)	4834
Current medication			
Medication free	69	68.5 (40.9)	1406
Antidepressant	87	32.9 (39.4)	930
SSRI	75	10.9 (15.8)	369
Tricyclic	74	6.9 (12.2)	215
MAOI	64	0.2 (0.9)	6
Other	69	8.8 (15.9)	289
Mood stabilizer	56	3.2 (8.7)	69
Antipsychotic	61	4.2 (12.3)	86

Abbreviations: HAM-D, Hamilton Scale for Depression; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor.

^aMany studies did not report the HAM-D scale version used (eg, 17 or 21 questions); the value given is the mean of all HAM-D values and is thus an approximation of depression severity.

The classification systems used for defining MDD were DSM-IV (156 studies); DSM-III-R (46 studies); DSM-III (13 studies); *International Classification of Diseases, Ninth Revision* or *International Classification of Diseases, Tenth Revision* (5 studies); Research Diagnostic Criteria²⁷ (4 studies); and Chinese Classification of Mental Disorders²⁸ (1 study). Two hundred eight studies used MRI and 17 studies used CT imaging. Among MRI studies, 81% used a 1.5-T scanner; 11% used a lower field strength and 6% used a higher field strength. The mean (SD) slice thickness was 9.0 (1.0) mm in CT studies and 2.8 (2.1) mm in MRI studies. There was evidence that studies were recruiting larger numbers of patients over time ($R=0.21$; $P=.002$) and that the number of studies per year was increasing ($R=0.94$; $P<.001$).

MDD META-ANALYSIS

The 143 studies included in the meta-analysis²⁹⁻¹⁷¹ are listed in **Table 2**. Compared with controls, patients with MDD had larger lateral ventricular and cerebrospinal fluid (CSF) volumes and smaller volumes of the total caudate, putamen, globus pallidus, thalamus, hippocampus, frontal lobe, orbitofrontal gray matter, and gyrus rectus (**Figure 1** and **Table 3**). The pituitary gland was increased in volume, with borderline significance ($P=.054$). Patients with MDD had moderately increased rates of MRI signal hyperintensities, but this was dependent on the measurement technique used. When hyper-

intensity rating scales were used, periventricular hyperintensities were increased (Figure 1 and Table 3); when categorical classification was used (patient classified as having hyperintensities or no hyperintensities), subcortical gray matter hyperintensities were increased (**Figure 2** and **Table 4**). The differences that survived Bonferroni correction ($P<.0008$) were increased lateral ventricle and CSF volume and decreased hippocampal and gyrus rectus volume (Table 3). No small-study bias was detected in any of the brain regions identified in this paragraph (all $P>.11$).

Effect of Clinical Variables on Hippocampal Volume

Because outliers may have a disproportionate effect on meta-regression analysis, 2 outliers^{113,167} were removed before investigating the effect of clinical variables on total hippocampal volume (effect sizes of outliers, -3.8 and -2.2 ; effect size range of the remaining 35 studies, -1.3 to $+0.4$; and pooled effect size after 2 studies were excluded, -0.40). There was no significant effect of age at onset (23 studies, $P=.75$), HAM-D score (18 studies, $P=.58$), percentage of patients using antidepressants (22 studies, $P=.61$), number of depressive episodes (20 studies, $P=.25$), or patient age (35 studies, $P=.54$) on the difference in hippocampal volume between patients and controls. For each meta-regression performed, the heterogeneity of the included studies remained significant ($I^2 > 28\%$). In terms of subgroups, patients with MDD in remission had a significantly larger hippocampal volume compared with patients who were currently depressed (4 studies, effect size, 0.34 ; 95% confidence interval, $0.02-0.67$; $P=.04$); there was no significant difference in volume between patients with remitted MDD and controls (5 studies, $P=.25$). In addition, there was no significant difference in hippocampal volume between patients with first episode vs multiple episodes (4 studies, $P=.32$) or patients with early- vs late-onset depression (3 studies, $P=.24$). The significant reduction in hippocampal volume remained when the meta-analysis was limited to first-episode studies (6 studies; effect size, -0.22 ; $P=.04$); studies that excluded patients with a comorbid anxiety disorder (10 studies; effect size, -0.39 ; $P<.001$); and studies that excluded patients with a history of drug abuse/dependence or substance abuse/dependence (6 studies; effect size, -0.32 ; $P<.001$), adults (mean age, 20-60 years; 22 studies; effect size, -0.43 ; $P<.001$), and elderly patients (60-75 years; 8 studies; effect size, -0.34 ; $P<.001$). Although the effect size was similar to that of other subgroups, there was no significant reduction of hippocampal volume in adolescent patients (12-19 years; 5 studies; effect size, -0.35 ; $P=.11$).

Sensitivity Analysis

When percentage change was used as the effect size for continuous data, there was a reduction in the volume of the right orbitofrontal cortex and an increase in deep white matter hyperintensities as measured by rating scales in patients with MDD, and the decrease previously observed in the globus pallidus became a trend. If ratio,

Table 2. List of Studies Included in the MDD Meta-analysis

Study	No. of MDD Patients	No. of Controls	Diagnostic Criteria	Mean Patient Age, y	Imaging Modality
Scott et al, ²⁹ 1983	10	10	DSM-III	39.2	CT
Iacono et al, ³⁰ 1988	16	44	DSM-III	22.6	CT
Pearlson et al, ³¹ 1989	11	31	DSM-III	70.0	CT
Andreasen et al, ³² 1990	27	75	DSM-III	37.3	CT
Coffey et al, ³³ 1990	35	22	DSM-III	71.7	MRI
Harvey et al, ³⁴ 1990	5	50	RDC	NA	CT
Zubenko et al, ³⁵ 1990	67	44	DSM-III-R	73.2	MRI
Husain et al, ³⁶ 1991	41	44	DSM-III-R	55.3	MRI
Lammers et al, ³⁷ 1991	20	20	DSM-III-R	53.8	MRI
Lewine et al, ³⁸ 1991	12	68	DSM-III	NA	MRI
Brown et al, ³⁹ 1992	28	154	DSM-III-R	40.3	MRI
Guze and Szuba, ⁴⁰ 1992	119	60	DSM-III-R	54.1	MRI
Krishnan et al, ⁴¹ 1992	50	50	DSM-III	48.3	MRI
Lauer et al, ⁴² 1992	14	12	DSM-III-R	40.7	CT
Shah et al, ⁴³ 1992	27	36	DSM-III	57.6	MRI
Axelsson et al, ⁴⁴ 1993	19	30	DSM-III	46.7	MRI
Krishnan et al, ⁴⁵ 1993	25	20	DSM-III	74.1	MRI
Lisanby et al, ⁴⁶ 1993	21	21	DSM-III-R	65.0	MRI
Wu et al, ⁴⁷ 1993	20	16	DSM-III-R	32.9	MRI
Lesser et al, ⁴⁸ 1994	39	20	DSM-III-R	60.9	MRI
Miller et al, ⁴⁹ 1994	19	23	DSM-III-R	69.0	MRI
Dupont et al, ⁵⁰ 1995	30	26	DSM-III-R	38.6	MRI
Dupont et al, ⁵¹ 1995	33	32	DSM-III-R	38.9	MRI
Lewine et al, ⁵² 1995	27	150	DSM-III-R	40.9	MRI
Wurthmann et al, ⁵³ 1995	34	43	DSM-III-R	70.7	CT
Elkis et al, ⁵⁴ 1996	24	40	DSM-III-R	38.7	CT
Greenwald et al, ⁵⁵ 1996	48	39	DSM-III-R	74.6	MRI
Keshavan et al, ⁵⁶ 1996	19	19	DSM-III-R	67.0	MRI
Lesser et al, ⁵⁷ 1996	95	165	DSM-III-R	61.0	MRI
Marchesi et al, ⁵⁸ 1996	11	11	DSM-III-R	64.8	CT
Drevets et al, ⁵⁹ 1997	17	21	DSM-III-R	35.0	MRI
Kumar et al, ⁶⁰ 1997	28	29	DSM-III-R	74.2	MRI
Pantel et al, ⁶¹ 1997	19	13	DSM-III-R	72.4	MRI
Pillay et al, ⁶² 1997	38	20	DSM-III-R	38.5	MRI
Kumar et al, ⁶³ 1998	35	30	DSM-IV	74.6	MRI
Parashos et al, ⁶⁴ 1998	72	38	DSM-III-R	55.4	MRI
Pillay et al, ⁶⁵ 1998	38	20	DSM-III-R	38.5	MRI
Sheline et al, ⁶⁶ 1998	20	20	DSM-IV	54.0	MRI
Ashtari et al, ⁶⁷ 1999	40	46	DSM-III-R	74.3	MRI
Kramer-Ginsberg et al, ⁶⁸ 1999	41	38	DSM-III-R	74.6	MRI
Lenze et al, ⁶⁹ 1999	24	24	DSM-IV	52.7	MRI
Lenze and Sheline, ⁷⁰ 1999	24	24	DSM-IV	53.0	MRI
Bremner et al, ⁷¹ 2000	16	16	DSM-IV	43.0	MRI
Kumar et al, ⁷² 2000	51	30	DSM-IV	74.3	MRI
Vakilil et al, ⁷³ 2000	38	20	DSM-III-R	38.5	MRI
Caetano et al, ⁷⁴ 2001	17	39	DSM-IV	42.8	MRI
Greenwald et al, ⁷⁵ 2001	81	70	DSM-III-R	74.7	MRI
McIntosh et al, ⁷⁶ 2001	9	29	DSM-III-R	43.6	MRI
Novaretti et al, ⁷⁷ 2001	30	20	ICD-10	71.0	MRI
Rusch et al, ⁷⁸ 2001	25	15	DSM-IV	33.2	MRI
Sassi et al, ⁷⁹ 2001	13	34	DSM-IV	41.2	MRI
Botteron et al, ⁸⁰ 2002	48	48	DSM-IV	26.1	MRI
Brambilla et al, ⁸¹ 2002	18	38	DSM-IV	42.0	MRI
Bremner et al, ⁸² 2002	15	20	DSM-IV	43.0	MRI
Frodl et al, ⁸³ 2002	30	30	DSM-IV	40.3	MRI
Nolan et al, ⁸⁴ 2002	22	22	DSM-IV	13.7	MRI
Pujol et al, ⁸⁵ 2002	57	37	DSM-IV	60.8	MRI
Salokangas et al, ⁸⁶ 2002	37	19	DSM-IV	36.0	MRI
Steingard et al, ⁸⁷ 2002	19	38	DSM-III-R	15.4	MRI
Tupler et al, ⁸⁸ 2002	115	37	DSM-III-R	66.7	MRI
Agid et al, ⁸⁹ 2003	37	27	DSM-IV	55.0	MRI
Almeida et al, ⁹⁰ 2003	51	37	DSM-IV	74.2	MRI
Frodl et al, ⁹¹ 2003	57	57	DSM-IV	44.5	MRI
Lacerda et al, ⁹² 2003	25	48	DSM-IV	41.2	MRI

(continued)

Table 2. List of Studies Included in the MDD Meta-analysis (continued)

Study	No. of MDD Patients	No. of Controls	Diagnostic Criteria	Mean Patient Age, y	Imaging Modality
MacMillan et al, ⁹³ 2003	23	23	DSM-IV	14.0	MRI
MacQueen et al, ⁹⁴ 2003	37	37	DSM-IV	28.4	MRI
Posener et al, ⁹⁵ 2003	27	42	DSM-IV	33.0	MRI
Sassi et al, ⁹⁶ 2003	18	38	DSM-IV	42.8	MRI
Sheline et al, ⁹⁷ 2003	38	38	DSM-IV	50.8	MRI
Silverstone et al, ⁹⁸ 2003	11	19	DSM-IV	34.4	MRI
Baldwin et al, ⁹⁹ 2004	50	35	DSM-IV	73.7	MRI
Ballmaier et al, ¹⁰⁰ 2004	17	17	DSM-IV	75.2	MRI
Ballmaier et al, ¹⁰¹ 2004	24	19	DSM-IV	65.9	MRI
Caetano et al, ¹⁰² 2004	31	31	DSM-IV	39.2	MRI
Hastings et al, ¹⁰³ 2004	18	18	DSM-III-R	38.9	MRI
Janssen et al, ¹⁰⁴ 2004	28	41	DSM-IV	64.0	MRI
Lacerda et al, ¹⁰⁵ 2004	31	34	DSM-IV	39.3	MRI
Lange and Irlie, ¹⁰⁶ 2004	17	17	DSM-IV	34.0	MRI
Lavretsky et al, ¹⁰⁷ 2004	41	41	DSM-IV	70.5	MRI
Lloyd et al, ¹⁰⁸ 2004	51	39	DSM-IV	74.0	MRI
MacMaster and Kusumakar, ¹⁰⁹ 2004	17	17	DSM-IV	16.7	MRI
MacMaster and Kusumakar, ¹¹⁰ 2004	17	17	DSM-IV	16.7	MRI
Supprian et al, ¹¹¹ 2004	10	10	DSM-IV	48.9	MRI
Vythilingam et al, ¹¹² 2004	38	33	DSM-IV	41.0	MRI
Xia et al, ¹¹³ 2004	22	13	CCMD	39.5	MRI
Chen et al, ¹¹⁴ 2005	39	20	DSM-IV	69.9	MRI
Coryell et al, ¹¹⁵ 2005	10	10	DSM-IV	21.9	MRI
Hickie et al, ¹¹⁶ 2005	51	20	DSM-IV	53.5	MRI
Iosifescu et al, ¹¹⁷ 2005	50	35	DSM-IV	40.6	MRI
Lacerda et al, ¹¹⁸ 2005	22	39	DSM-IV	41.4	MRI
Lavretsky et al, ¹¹⁹ 2005	41	41	DSM-IV	70.5	MRI
Lin et al, ¹²⁰ 2005	37	18	DSM-IV	72.2	MRI
Rosso et al, ¹²¹ 2005	20	24	DSM-IV	15.4	MRI
Taylor et al, ¹²² 2005	135	83	DSM-IV	70.0	MRI
Caetano et al, ¹²³ 2006	31	31	DSM-IV	39.2	MRI
Frodl et al, ¹²⁴ 2006	34	34	DSM-IV	45.5	MRI
Hannestad et al, ¹²⁵ 2006	182	64	DSM-IV	70.2	MRI
Iosifescu et al, ¹²⁶ 2006	84	35	DSM-III-R	40.5	MRI
MacMaster et al, ¹²⁷ 2006	35	35	DSM-IV	14.5	MRI
Naish et al, ¹²⁸ 2006	29	22	DSM-IV	71.0	MRI
Saylam et al, ¹²⁹ 2006	24	24	DSM-IV	33.4	MRI
Velakoulis et al, ¹³⁰ 2006	12	87	DSM-III-R	22.6	MRI
Weniger et al, ¹³¹ 2006	21	23	DSM-IV	34.0	MRI
Caetano et al, ¹³² 2007	19	24	DSM-IV	13.0	MRI
Colla et al, ¹³³ 2007	24	14	DSM-IV	54.5	MRI
Hickie et al, ¹³⁴ 2007	45	16	DSM-IV	52.0	MRI
Lavretsky et al, ¹³⁵ 2007	43	41	DSM-IV	70.7	MRI
Maller et al, ¹³⁶ 2007	45	30	DSM-IV	37.4	MRI
Munn et al, ¹³⁷ 2007	26	18	DSM-IV	20.5	MRI
Taylor et al, ¹³⁸ 2007	226	144	DSM-IV	70.0	MRI
Andreescu et al, ¹³⁹ 2008	71	32	DSM-IV	72.2	MRI
Ballmaier et al, ¹⁴⁰ 2008	46	34	DSM-IV	71.1	MRI
Ballmaier et al, ¹⁴¹ 2008	46	34	DSM-IV	71.1	MRI
Chen et al, ¹⁴² 2008	27	26	DSM-IV	14.4	MRI
Eker et al, ¹⁴³ 2008	34	39	DSM-IV	31.7	MRI
Elderkin-Thompson et al, ¹⁴⁴ 2008	43	41	DSM-IV	70.7	MRI
Frodl et al, ¹⁴⁶ 2008	78	78	DSM-IV	44.7	MRI
Keller et al, ¹⁴⁷ 2008	42	22	DSM-IV	36.5	MRI
Lenze et al, ¹⁴⁸ 2008	31	24	DSM-IV	50.0	MRI
MacMaster et al, ¹⁴⁹ 2008	32	35	DSM-IV	14.1	MRI
Matsuo et al, ¹⁵⁰ 2008	27	26	DSM-IV	14.4	MRI
Tae et al, ¹⁵¹ 2008	21	20	DSM-IV	41.7	MRI
Zanetti et al, ¹⁵² 2008	28	102	DSM-IV	30.5	MRI
Bergouignan et al, ¹⁵³ 2009	21	21	DSM-IV	33.2	MRI
Elderkin-Thompson et al, ¹⁴⁵ 2009	26	23	DSM-IV	70.0	MRI
Exner et al, ¹⁵⁴ 2009	35	26	DSM-IV	34.5	MRI
Jessen et al, ¹⁵⁵ 2009	79	84	DSM-IV	48.2	MRI
Kronenberg et al, ¹⁵⁶ 2009	24	14	DSM-IV	54.5	MRI

(continued)

Table 2. List of Studies Included in the MDD Meta-analysis (continued)

Study	No. of MDD Patients	No. of Controls	Diagnostic Criteria	Mean Patient Age, y	Imaging Modality
Kronmüller et al, ¹⁵⁷ 2009	57	30	DSM-IV	43.5	MRI
Lorenzetti et al, ¹⁵⁸ 2009	56	33	DSM-IV	33.7	MRI
Milne et al, ¹⁵⁹ 2009	28	14	DSM-IV	39.7	MRI
Pan et al, ¹⁶⁰ 2009	170	83	DSM-IV	69.4	MRI
Penttilä et al, ¹⁶¹ 2009	35	70	DSM-IV	47.2	MRI
Pizzagalli et al, ^{162e} 2009	30	31	DSM-IV	43.2	MRI
Sun et al, ¹⁶³ 2009	45	30	DSM-IV	40.8	MRI
Tamburo et al, ¹⁶⁴ 2009	14	11	DSM-IV	69.8	MRI
van Eijndhoven et al, ¹⁶⁵ 2009	40	20	DSM-IV	35.7	MRI
Walterfang et al, ¹⁶⁶ 2009	54	32	DSM-IV	34.3	MRI
Kaymak et al, ¹⁶⁷ 2010	20	15	DSM-IV	32.0	MRI
Köhler et al, ¹⁶⁸ 2010	35	29	DSM-IV	74.1	MRI
Lorenzetti et al, ¹⁶⁹ 2010	56	31	DSM-IV	33.7	MRI
Meisenzahl et al, ¹⁷⁰ 2010	92	138	DSM-IV	44.6	MRI
Weber et al, ¹⁷¹ 2010	38	62	DSM-IV	66.1	MRI

Abbreviations: CCMD, Chinese Classification of Mental Disorders; CT, computed tomography; MDD, major depressive disorder; MRI, magnetic resonance imaging; NA, not available; RDC, Research Diagnostic Criteria.

length, and area measurements were excluded, lateral, ventricle measures using CT imaging could not be included because all studies reported a ventricle to brain ratio measure; no other changes were noted. There was no change in the results when the correlation coefficient between left and right regions was set to 0, 0.5, or 1.

COMPARISON WITH BD

Stratified Meta-analysis

Nine regions included in both the MDD and BD meta-analyses showed significant differences from controls, allowing a comparison to be made (**Table 5**). Six of these regions differed between MDD and BD. Compared with BD patients or controls, patients with MDD had significantly reduced volumes of the caudate, putamen, globus pallidus, and hippocampus. Compared with MDD patients or controls, patients with BD had significantly reduced cross-sectional areas of the corpus callosum and increased rates of deep white matter hyperintensities. Compared with controls, both MDD and BD patients showed ventricular dilation and increased rates of subcortical gray matter hyperintensities, but there was no significant difference between the patient groups.

Verifying Diagnostic Differences

When we examined differences in study characteristics between BD and MDD investigations for each of the 6 brain regions identified in the previous paragraph, there were significant differences in terms of patient age (5 regions), sex (3 regions), and medication use (5 regions), but no significant differences in terms of scanner field strength or slice thickness. From the follow-up meta-regression analyses, there was no significant effect of patient age, sex, or medication use on any of the 6 regions in either BD or MDD studies. One exception was patient age in BD studies, in which increased age was associated with increased hippocampal volume compared with matched controls ($P=.001$).

COMMENT

In patients with MDD compared with controls, we identified increased lateral ventricle and CSF volume; reduced volume of the basal ganglia, thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus; and increased rates of periventricular and subcortical gray matter hyperintensities. Currently depressed MDD patients had smaller hippocampal volumes vs those with remitted MDD. Within mood disorders, basal ganglia and hippocampal volume reductions appear to be specific to MDD, and reduced corpus callosum cross-sectional area and increased rates of deep white matter hyperintensities appear to be specific to BD.

HIPPOCAMPUS AND HYPOTHALAMIC-PITUITARY-ADRENAL AXIS

In MDD patients compared with controls, we found bilateral reductions in hippocampal volume (-5%) as reported by previous meta-analyses,^{12,13,174} and also showed a strong significant trend for increased pituitary volume ($P=.054$, 5%). These findings may provide evidence for the involvement of the hypothalamic-pituitary-adrenal axis in MDD. The anterior pituitary produces adrenocorticotropic hormone, and it is conceivable that an increased volume of the pituitary may be associated with increased adrenocorticotropic hormone production. A primary role of adrenocorticotropic hormone is stimulation of the adrenal cortex, which responds by producing glucocorticoids. There is strong evidence that glucocorticoid levels are increased in MDD, and prolonged high levels may damage hippocampal neurons.¹⁷⁵ A small number of studies measured the adrenal gland in MDD; these were not included in our meta-analysis because only 2 (not meeting our criterion of 3) measured this structure in a group including only patients with MDD. However, because of the weight of evidence supporting the involvement of the hypothalamic-




Figure 1. Continuous variables evaluated in major depressive disorder (MDD) meta-analysis. Hedges *g* (Cohen effect size with small sample correction) is shown for each structure, with 95% confidence intervals. The effect size is positive when the structure is larger in patients with MDD compared with controls and negative when the structure is smaller in MDD patients. The number of studies included in each meta-analysis is indicated with each structure. CSF indicates cerebrospinal fluid; CT, computed tomography; DWMH, deep white matter hyperintensities; GM, gray matter; L, left; MRI, magnetic resonance imaging; PFC, prefrontal cortex; PVH, periventricular hyperintensities; R, right; ScGMH, subcortical gray matter hyperintensities; and WM, white matter.

pituitary-adrenal axis, we entered these studies into an additional meta-analysis (not previously reported). The 3 case-control studies comprised 1 MRI study that evaluated 3 BD patients with 32 MDD patients as a single group¹⁷⁶ and 2 CT studies of MDD patients.^{177,178} Adrenal volume was significantly increased compared with controls (effect size, 0.81; 95% confidence interval, 0.45-1.16; $P < .0001$), providing further evidence of an association between MDD and hypothalamic-pituitary-adrenal axis abnormalities. The finding that hippocampal volume was significantly smaller in patients with a depressed compared with remitted state raises the possibility that reductions in hippocampal volume may normalize during remission, and it is tempting to speculate

that this may be the result of neurogenesis in the dentate gyrus.¹⁷⁹ A longitudinal study performing scans on the same patients during depression and after recovery would be an effective way of examining these putative changes in more detail. Although we did not detect an association between antidepressant use and hippocampal volume, there is growing evidence that antidepressants may upregulate neurogenesis. Malberg et al¹⁸⁰ reported that chronic antidepressant therapy increased neurogenesis in rats and an antipsychotic medication had no effect. More recently, a postmortem study¹⁸¹ reported that depressed patients who had been treated with antidepressants had an increased number of neural progenitor cells in the dentate gyrus compared with un-

Table 3. Meta-analysis of Continuous Data Comparing Patients With MDD vs Controls^a

Region	No. of Studies	No. of MDD/Controls ^a	MDD Patients vs Controls			Heterogeneity			SS Bias, P Value ^d
			Effect Size (95% CI)	Effect Size P Value ^b	Size vs Controls, %	Q	I ² c (%)	P Value	
Lateral ventricles, total	15	371/539	0.44 (0.24 to 0.63)	.00001^e	122.4	25	39	.06	.15
Lateral ventricles, MRI	6	220/224	0.41 (0.13 to 0.68)	.004	124.0	8	40	.14	.59
Lateral ventricles, CT	9	151/315	0.47 (0.18 to 0.76)	.0016	121.4	16	45	.06	.20
Fourth ventricle	3	46/75	0.03 (-0.35 to 0.41)	.86	103.6	2	1	.36	
CSF, total	8	259/218	0.54 (0.26 to 0.82)	.00014^e	113.9	19	52	.03	.60
Intracranial volume	21	765/811	-0.07 (-0.20 to 0.06)	.30	99.4	37	36	.04	
Brain	28	1187/1014	-0.06 (-0.16 to 0.04)	.24	99.2	37	13	.26	
Cerebrum	7	392/283	-0.11 (-0.27 to 0.04)	.15	98.8	5	0	.56	
GM, total	8	261/253	-0.10 (-0.28 to 0.08)	.27	98.9	5	0	.87	
WM, total	6	196/157	-0.19 (-0.42 to 0.05)	.12	98.1	8	11	.35	
Caudate, total	13	586/391	-0.22 (-0.38 to -0.06)	.0063	96.5	15	22	.22	.57
Caudate, left	8	347/258	-0.07 (-0.25 to 0.10)	.40	98.6	4	0	.75	
Caudate, right	8	347/258	-0.05 (-0.22 to 0.12)	.59	99.1	6	0	.55	
Putamen, total	8	460/298	-0.25 (-0.43 to -0.06)	.0087	95.9	10	28	.21	.69
Putamen, left	6	313/256	-0.21 (-0.49 to 0.07)	.15	95.9	12	57	.04	
Putamen, right	6	313/256	-0.23 (-0.52 to 0.05)	.11	95.1	12	58	.03	
Globus pallidus, total	3	122/111	-0.31 (-0.61 to -0.02)	.04	95.5	2	13	.32	
Thalamus, total	7	245/205	-0.34 (-0.60 to -0.07)	.012	93.3	10	40	.12	.78
Temporal lobe, total	6	164/152	-0.36 (-0.76 to 0.04)	.08	95.5	14	65	.02	
Temporal lobe, left	5	113/122	-0.32 (-0.74 to 0.10)	.14	96.0	9	57	.05	
Temporal lobe, right	5	113/122	-0.14 (-0.59 to 0.30)	.53	98.3	10	62	.03	
Hippocampus, total	37	1377/1281	-0.47 (-0.62 to -0.32)	<.00001^e	94.5	131	67	<.01	.14
Hippocampus, left	35	1248/1214	-0.44 (-0.60 to -0.28)	<.00001^e	94.7	130	68	<.01	.11
Hippocampus, right	34	1220/1200	-0.45 (-0.60 to -0.30)	<.0001^e	94.5	119	66	<.01	.15
Amygdala-hippocampal complex, total	4	87/118	-0.15 (-0.43 to 0.14)	.31	97.8	1	0	.78	
Amygdala-hippocampal complex, right	3	47/72	-0.05 (-0.43 to 0.33)	.80	99.1	0	0	.84	
Amygdala-hippocampal complex, left	3	47/72	-0.03 (-0.42 to 0.35)	.86	99.3	0	0	.80	
Amygdala, total	21	633/583	-0.07 (-0.31 to 0.16)	.54	98.8	87	73	<.01	
Amygdala, left	19	517/535	0.08 (-0.13 to 0.29)	.46	101.0	58	62	<.01	
Amygdala, right	19	517/535	-0.08 (-0.33 to 0.16)	.51	98.9	77	71	<.01	
Anterior cingulate, total	6	276/264	-0.21 (-0.53 to 0.12)	.22	96.0	17	70	<.01	
Anterior cingulate, left	4	190/212	-0.09 (-0.69 to 0.52)	.78	99.3	26	88	<.01	
Anterior cingulate, right	4	190/212	-0.18 (-0.44 to 0.08)	.17	95.3	5	40	.17	
Frontal, total, GM + WM	7	262/213	-0.29 (-0.53 to -0.05)	.02	96.2	12	34	.14	.46
Frontal, left, GM + WM	5	139/145	-0.11 (-0.36 to 0.13)	.35	98.6	4	0	.74	
Frontal, right, GM + WM	5	139/145	-0.13 (-0.37 to 0.11)	.28	98.9	4	0	.68	
Frontal, total, GM	6	171/166	-0.08 (-0.30 to 0.14)	.48	98.8	7	0	.44	
Frontal, left, GM	5	153/129	-0.19 (-0.43 to 0.05)	.12	98.4	4	0	.69	
Frontal, right, GM	5	153/129	-0.10 (-0.34 to 0.14)	.39	99.0	4	0	.67	
Frontal, total, WM	5	152/153	-0.10 (-0.41 to 0.22)	.54	99.1	10	42	.11	
Frontal, left, WM	4	134/116	0.01 (-0.25 to 0.26)	.95	99.7	4	0	.60	
Frontal, right, WM	4	134/116	-0.08 (-0.37 to 0.21)	.60	98.7	6	21	.28	
Orbitofrontal, total GM + WM	3	140/105	-0.23 (-0.66 to 0.20)	.30	95.4	7	59	.06	

(continued)

treated patients or controls. In previous meta-analyses, Videbech and Ravnkilde¹² reported that increased duration of illness was associated with smaller right hippocampal volume, and McKinnon et al¹⁴ did not find hippocampal reduction in first episodes of MDD. Conversely, we did not find an association with duration of illness and determined that hippocampal volume reduction was present in patients at first episode. However, in our analysis, the effect size in first-episode studies (0.22) was numerically less than that in all studies combined (0.47), suggesting that the volumetric reduction may be less marked in the early stages of the illness.

VOLUME REDUCTIONS IN THE FRONTAL LOBE AND BASAL GANGLIA

Four frontal regions were smaller in MDD patients compared with controls. Although we could not confirm that the subgenual prefrontal cortex was reduced in volume in MDD, it is possible that functional,^{59,182} rather than structural, abnormalities are of greater prominence in this region. The most significant effect sizes were observed in the orbitofrontal cortex and gyrus rectus. Deficits of prefrontal cortical activation in MDD are relatively consistent in functional neuroimaging studies,¹⁸³ and post-

Table 3. Meta-analysis of Continuous Data Comparing Patients With MDD vs Controls^a (continued)

Region	No. of Studies	No. of MDD/Controls ^a	MDD Patients vs Controls			Heterogeneity ^c			SS Bias, P Value ^d
			Effect Size (95% CI)	Effect Size P Value ^b	Size vs Controls, %	Q	I ² (%)	P Value	
Orbitofrontal, total, GM	6	424/318	-0.38 (-0.64 to -0.11)	.0054	92.5	14	57	.03	.41
Orbitofrontal, left, GM	5	355/286	-0.29 (-0.57 to -0.02)	.037	93.1	9	55	.06	.99
Orbitofrontal, right, GM	5	355/286	-0.24 (-0.51 to 0.04)	.09	94.6	9	56	.06	
Medial orbitofrontal, total, GM	3	86/101	-0.12 (-0.54 to 0.30)	.58	97.2	4	52	.13	
Lateral orbitofrontal, total, GM	3	86/101	-0.02 (-0.52 to 0.48)	.95	99.7	6	66	.05	
Subgenual PFC, total	7	234/265	-0.14 (-0.36 to 0.07)	.20	94.4	8	17	.30	
Subgenual PFC, left	6	171/173	-0.35 (-0.78 to 0.08)	.11	88.5	17	65	<.01	
Subgenual PFC, right	5	154/152	-0.07 (-0.31 to 0.17)	.59	96.6	5	2	.40	
Gyrus rectus, total, GM	3	112/75	-0.72 (-1.03 to -0.41)	<.00001^e	84.5	1	0	.48	
Corpus callosum, area	6	233/175	0.06 (-0.29 to 0.41)	.75	101.5	17	65	<.01	
Anterior corpus callosum, area	4	133/119	-0.18 (-0.86 to 0.50)	.60	97.6	20	85	<.01	
Corpus callosum, length	4	96/87	-0.06 (-0.58 to 0.45)	.81	99.6	9	65	.04	
Pituitary	5	161/158	0.25 (0.00 to 0.50)	.054	105.4	7	18	.30	
DWMH, rating ^f	9	357/318	0.17 (-0.01 to 0.36)	.07	116.4	15	27	.18	
PVH, rating^f	9	324/287	0.29 (0.08 to 0.50)	.006	122.4	17	35	.11	.21
ScGMH, rating ^f	6	246/241	0.14 (-0.15 to 0.43)	.34	116.4	16	57	.02	

Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; CT, computed tomography; DWMH, deep white matter hyperintensities; GM, gray matter; MDD, major depressive disorder; MRI, magnetic resonance imaging; PFC, prefrontal cortex; PVH, periventricular hyperintensities; ScGMH, subcortical gray matter hyperintensities; SS, small study; WM, white matter.

^a Pooled numbers of patients and controls.

^b Boldface indicates significant differences in effect sizes.

^c Low, 25%; moderate, 50%; and high, 75%.

^d Small-study bias was calculated only when there was a significant difference between patients and controls and when at least 5 studies were included in the meta-analysis to ensure that the test was sufficiently powered.

^e Result remained significant after Bonferroni correction for multiple comparisons.

^f The hyperintensity rating categories included the scales from Coffey et al,³³ Fazekas et al,¹⁷² and Scheltens et al.¹⁷³




Figure 2. Categorical variables evaluated in major depressive disorder (MDD) meta-analysis. Odds ratio is shown for each type of hyperintensity, with 95% confidence intervals. Odds ratio larger than 1 indicates that the hyperintensity is more common in patients with MDD compared with control group members. The number of studies included in each meta-analysis is indicated with each type of hyperintensity. GM indicates gray matter; MRI, magnetic resonance imaging; and WM, white matter.

mortem studies¹⁸⁴ have reported reduced neuronal and glial density in the dorsal lateral and orbitofrontal cortex. We confirm the findings of a previous meta-analysis,¹³ which reported reduced volume of the caudate and putamen in patients with MDD, but we also found significant volume reductions of the globus pallidus. Although the basal ganglia have primarily been linked to motor function, the ventral striatum, including the nucleus accumbens, has been strongly associated with limbic systems, particularly reward networks.¹⁸⁵

MRI SIGNAL HYPERINTENSITIES

Although increased rates of hyperintensities are considered an established finding in MDD, particularly in older patients,¹⁸⁶ our meta-analysis showed only modest increases compared with healthy controls. The reported effect sizes in this meta-analysis were smaller than those in 2 earlier meta-analyses^{16,187} of depression studies. Our meta-analysis included only studies on patients with MDD; however, both previous meta-analyses included studies that evaluated MDD and BD patients as a single group,¹⁸⁸⁻¹⁹⁰ which may have inflated the effect size. Indeed, our study indicates that patients with BD have more than a 2-fold increase in rates of deep white matter hyperintensities compared with MDD patients (Table 5).

COMPARISON WITH VBM STUDIES

We excluded reports on VBM from the meta-analysis; however, a qualitative review of these studies partially supports our findings. In 12 VBM studies that examined gray matter volume, the most consistent findings were hippocampal volume reduction (7 studies)¹⁹¹⁻¹⁹⁷ and volumetric reductions within the frontal lobe (7 studies).^{191,192,194-196,198,199} Changes shown with VBM that were not found in our meta-analysis included reductions within the amygdala (4 studies)^{194-196,200} and cingulate cortex (6 studies),^{193-195,199-201} although 1 study¹⁹⁸ found an increase in volume.

Table 4. Meta-analysis of Categorical Data Comparing Patients With MDD vs Controls

Abnormality	No. of Studies	No. of MDD/Controls ^a	MDD Patients vs Controls		Heterogeneity			SS Bias, P Value ^d
			OR (95% CI)	OR P Value ^b	Q	I ² c (%)	P Value	
Any MRI hyperintensities	10	491/532	1.60 (0.94 to 2.73)	.08	24	63	<.01	
Deep WM hyperintensities	14	765/957	1.09 (0.84 to 1.42)	.51	9	0	.77	
Periventricular WM hyperintensities	11	419/498	1.17 (0.73 to 1.89)	.52	11	8	.37	
Subcortical GM hyperintensities	8	503/343	1.90 (1.05 to 3.41)	.03	12	40	.12	.99

Abbreviations: CI, confidence interval; GM, gray matter; MDD, major depressive disorder; MRI, magnetic resonance imaging; OR, odds ratio; SS, small-study; WM, white matter.

^aPooled numbers of patients and controls.

^bBoldface indicates a significant difference.

^cLow, 25%; moderate, 50%; and high, 75%.

^dSmall-study bias was calculated only when there was a significant difference between patients and controls and when at least 5 studies were included in the meta-analysis to ensure that the test was sufficiently powered.

Table 5. Statistical Comparison of the Present MDD Meta-analysis With a Previous Meta-analysis of BD⁹

Region	MDD vs Control Meta-analysis			BD vs Control Meta-Analysis			MDD vs BD ^a	
	No. of Studies	Effect Size	P Value	No. of Studies	Effect Size	P Value	Effect Size	P Value
Lateral ventricles, total	15	0.44	<.001	17	0.39	<.001	0.04	.73
Caudate, total	13	-0.22	.006	17	0.03	.69	-0.25	.03
Putamen, total	8	-0.25	.009	10	0.05	.56	-0.30	.02
Globus pallidus, total	3	-0.31	.04	6	0.39	.10	-0.70	.01
Thalamus, total	7	-0.34	.01	13	-0.05	.73	-0.29	.13
Hippocampus, total	37	-0.47	<.001	18	-0.06	.48	-0.41	<.001
Corpus callosum, cross-sectional area	6	0.06	.75	4	-0.43	.006	0.49	.04
DWMH	14	OR, 1.09	.51	13	OR, 2.49	<.001	OR, 0.44	.001
ScGMH	8	OR, 1.90	.03	6	OR, 2.84	.01	OR, 0.67	.42

Abbreviations: BD, bipolar disorder; DWMH, deep white matter hyperintensities; MDD, major depressive disorder; OR, odds ratio; ScGMH, subcortical gray matter hyperintensities.

^aFor the MDD vs BD comparison, negative effect sizes indicate that the region is smaller in MDD patients; positive effect sizes indicate that the region is smaller in BD patients. An OR less than 1 indicates that hyperintensities are less common in MDD patients compared with BD patients. Effect sizes for BD have been recalculated by combining left and right measures (see the "Methods" section) and, as such, may vary from those reported in the previous BD meta-analysis.⁹ Boldface indicates significant differences between BD and MDD patients.

MDD STRUCTURAL CHANGES COMPARED WITH BD

Based on findings from a large number of independent studies in the meta-analysis comparison, MDD is associated with reductions in basal ganglia and hippocampal volume, and BD is more strongly associated with white matter abnormalities, specifically deep white matter hyperintensities and reduced corpus callosum area. In terms of similarities, both disorders showed ventricular enlargement and increased rates of subcortical gray matter hyperintensities. The positive association between patient age and hippocampal volume in the BD sample reinforces the identified difference in hippocampal volume between patients with MDD and those with BD; if studies on BD had recruited older patients in the same way as MDD studies did, the difference would have been greater. The larger extent of gray matter volume reductions in MDD was surprising, given that BD is considered a more chronic illness and is associated with an earlier age at onset² and more episodes of major depression compared with MDD.⁴ The finding that white matter abnormalities were more strongly associated with BD than MDD was also unexpected; however, this is supported in

a review by Mahon et al.²⁰² who reported evidence of abnormal white matter in BD from studies using a variety of neuroimaging techniques in addition to neuropathologic and genetic studies. Because studies of twins have shown that there are both overlapping and distinct genetic risk factors for BD and MDD,²⁰³ it is possible that the unique genetic factors for each disorder are associated with the distinct structural abnormalities identified in this meta-analysis. Twin studies have also shown that environmental factors have a stronger influence in MDD than in BD.²⁰⁴ It is possible that the reduction in hippocampal volume observed in MDD but not BD is linked to stressful life events playing a more prominent role in the development of MDD.

LIMITATIONS

Although the case-control meta-analysis is statistically highly powered, the meta-regression analysis of clinical variables lacks power and may be prone to type I and type II errors. In the comparison between MDD and BD, we limited the analysis to regions that were significantly different from controls in either the MDD or BD meta-analysis. This strategy reduces the number of comparisons and associated type I

errors; however, it is possible that brain regions that distinguish the disorders were overlooked. Although we attempted to take into account differences in medications between the groups, it was not possible to account for this entirely because of the limited information reported in studies. A previous meta-analysis of BD studies⁹ and other studies^{205,206} have shown that use of lithium may increase gray matter volume, and it is possible that lithium may be masking abnormalities that would have been observed if patients with BD were not using this medication. The results from a long-term prospective study²⁰⁷ suggest an approximate 1% conversion rate from MDD to BD every year, which complicates the comparison of MDD and BD studies. Therefore, it is possible that the differences in brain structure between MDD patients who do not convert and BD patients are more pronounced than the differences reported in this study.

In conclusion, in this meta-analysis, we have shown robust structural brain abnormalities in MDD and particular changes in brain volume that may distinguish MDD from BD. These results may aid imaging studies aiming to use structural MRI data to distinguish patients with MDD from those with BD. Further studies may reveal whether these abnormalities are a risk factor for developing MDD, when they first occur, and whether they are predictive of treatment response.

Submitted for Publication: April 22, 2010; final revision received September 28, 2010; accepted November 30, 2010.

Author Affiliations: Section of Neurobiology of Psychosis, Department of Psychosis Studies (Drs Kempton and Frangou and Ms Salvador), Department of Neuroimaging (Drs Kempton, Simmons, and Williams), Institute of Psychiatry, King's College London, and National Institute for Health Research Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service Foundation Trust (Dr Simmons), London, England; Department of Experimental Psychology, University of Bristol, Bristol, England (Dr Munafò); and Department of Psychiatry, University of Oxford, Oxford, England (Dr Geddes).

Correspondence: Matthew J. Kempton, MSc, PhD, Department of Neuroimaging, PO89, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, England (matthew.kempton@kcl.ac.uk).

Author Contributions: Dr Kempton had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.

Funding/Support: The authors acknowledge financial support from the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London, and the ongoing support of the Wellcome Trust and Engineering and Physical Sciences Research Council toward the Medical Engineering Centre within King's College London. Dr Kempton was also supported by a Wellcome Trust Value in People Award.

Role of Sponsors: The sponsors of the study had no role in the design or conduct of this study; in the collection, management, analysis, and interpretation of the data; or

in the preparation, review, or approval of the manuscript.

Additional Contributions: Magaly Cermeño, BEng, independently verified data entered into the meta-analysis.

REFERENCES

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 2003;289(23):3095-3105.
2. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry*. 2007;64(5):543-552.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593-602.
4. Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *Am J Psychiatry*. 2006;163(2):225-231.
5. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. *JAMA*. 2002;287(2):203-209.
6. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. *Am J Psychiatry*. 2002;159(6):1005-1010.
7. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. *Neurosci Biobehav Rev*. 2009;33(5):699-771.
8. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. *Bipolar Disord*. 2008;10(1):1-37.
9. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. *Arch Gen Psychiatry*. 2008;65(9):1017-1032.
10. Arnott D, Cavanagh J, Gerber D, Lawrie SM, Ebmeier KP, McIntosh AM. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. *Br J Psychiatry*. 2009;195(3):194-201.
11. Vita A, De Peri L, Sacchetti E. Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies. *Bipolar Disord*. 2009;11(8):807-814.
12. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. *Am J Psychiatry*. 2004;161(11):1957-1966.
13. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Hum Brain Mapp*. 2009;30(11):3719-3735.
14. McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. *J Psychiatry Neurosci*. 2009;34(1):41-54.
15. Hamilton JP, Siemer M, Gotlib IH. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Mol Psychiatry*. 2008;13(11):993-1000.
16. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. *Acta Psychiatr Scand*. 1997;96(3):157-168.
17. Hoffmann R. A wiki for the life sciences where authorship matters. *Nat Genet*. 2008;40(9):1047-1051.
18. Eaton WW, Neufeld K, Chen LS, Cai G. A comparison of self-report and clinical diagnostic interviews for depression: diagnostic interview schedule and schedules for clinical assessment in neuropsychiatry in the Baltimore epidemiologic catchment area follow-up. *Arch Gen Psychiatry*. 2000;57(3):217-222.
19. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960;23:56-62.
20. Hedges LV, Olkin I. *Statistical Methods for Meta-analysis*. Orlando, FL: Academic Press; 1985.
21. McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalidindi S, Murray RM, Kennedy N. Meta-analysis of magnetic resonance imaging brain morphology studies in bipolar disorder. *Biol Psychiatry*. 2004;56(6):411-417.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.
23. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. *Am J Psychiatry*. 2000;157(1):16-25.

24. Sutton AJ. *Methods for Meta-analysis in Medical Research*. New York, NY: John Wiley & Sons; 2000.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.
27. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry*. 1978;35(6):773-782.
28. Chen YF. Chinese Classification of Mental Disorders (CCMD-3): towards integration in international classification. *Psychopathology*. 2002;35(2-3):171-175.
29. Scott ML, Golden CJ, Ruedrich SL, Bishop RJ. Ventricular enlargement in major depression. *Psychiatry Res*. 1983;8(2):91-93.
30. Iacono WG, Smith GN, Moreau M, Beiser M, Fleming JA, Lin TY, Flak B. Ventricular and sulcal size at the onset of psychosis. *Am J Psychiatry*. 1988;145(7):820-824.
31. Pearson GD, Rabins PV, Kim WS, Speedie LJ, Moberg PJ, Burns A, Bascom MJ. Structural brain CT changes and cognitive deficits in elderly depressives with and without reversible dementia ("pseudodementia"). *Psychol Med*. 1989;19(3):573-584.
32. Andreasen NC, Swayze V II, Flaum M, Alliger R, Cohen G. Ventricular abnormalities in affective disorder: clinical and demographic correlates. *Am J Psychiatry*. 1990;147(7):893-900.
33. Coffey CE, Figiel GS, Djang WT, Weiner RD. Subcortical hyperintensity on magnetic resonance imaging: a comparison of normal and depressed elderly subjects. *Am J Psychiatry*. 1990;147(2):187-189.
34. Harvey I, Williams M, Toone BK, Lewis SW, Turner SW, McGuffin P. The ventricular-brain ratio (VBR) in functional psychoses: the relationship of lateral ventricular and total intracranial area. *Psychol Med*. 1990;20(1):55-62.
35. Zubenko GS, Sullivan P, Nelson JP, Belle SH, Huff FJ, Wolf GL. Brain imaging abnormalities in mental disorders of late life. *Arch Neurol*. 1990;47(10):1107-1111.
36. Husain MM, McDonald WM, Doraiswamy PM, Figiel GS, Na C, Escalona PR, Boyko OB, Nemeroff CB, Krishnan KR. A magnetic resonance imaging study of putamen nuclei in major depression. *Psychiatry Res*. 1991;40(2):95-99.
37. Lammers CH, Doraiswamy PM, Husain MM, Figiel GS, Lurie SN, Boyko OB, Ellinwood EH Jr, Nemeroff CB, Krishnan KR. MRI of corpus callosum and septum pellucidum in depression. *Biol Psychiatry*. 1991;29(3):300-301.
38. Lewine RR, Risch SC, Risby E, Stipetic M, Jewart RD, Eccard M, Caudle J, Polard W. Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. *Am J Psychiatry*. 1991;148(9):1189-1194.
39. Brown FW, Lewine RJ, Hudgins PA, Risch SC. White matter hyperintensity signals in psychiatric and nonpsychiatric subjects. *Am J Psychiatry*. 1992;149(5):620-625.
40. Guze BH, Szuba MP. Leukoencephalopathy and major depression: a preliminary report. *Psychiatry Res*. 1992;45(3):169-175.
41. Krishnan KR, McDonald WM, Escalona PR, Doraiswamy PM, Na C, Husain MM, Figiel GS, Boyko OB, Ellinwood EH, Nemeroff CB. Magnetic resonance imaging of the caudate nuclei in depression: preliminary observations. *Arch Gen Psychiatry*. 1992;49(7):553-557.
42. Lauer CJ, Wiegand M, Krieg JC. All-night electroencephalographic sleep and cranial computed tomography in depression: a study of unipolar and bipolar patients. *Eur Arch Psychiatry Clin Neurosci*. 1992;242(2-3):59-68.
43. Shah SA, Doraiswamy PM, Husain MM, Escalona PR, Na C, Figiel GS, Patterson LJ, Ellinwood EH Jr, McDonald WM, Boyko OB, Nemeroff CB, Krishnan KR. Posterior fossa abnormalities in major depression: a controlled magnetic resonance imaging study. *Acta Psychiatr Scand*. 1992;85(6):474-479.
44. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, Nemeroff CB, Ellinwood EH Jr, Krishnan KR. Hypercortisolemia and hippocampal changes in depression. *Psychiatry Res*. 1993;47(2):163-173.
45. Krishnan KR, McDonald WM, Doraiswamy PM, Tupler LA, Husain M, Boyko OB, Figiel GS, Ellinwood EH Jr. Neuroanatomical substrates of depression in the elderly. *Eur Arch Psychiatry Clin Neurosci*. 1993;243(1):41-46.
46. Lisanby SH, McDonald WM, Massey EW, Doraiswamy PM, Rozear M, Boyko OB, Krishnan KR, Nemeroff C. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. *J Neural Transm Suppl*. 1993;40:13-21.
47. Wu JC, Buchsbaum MS, Johnson JC, Hershey TG, Wagner EA, Teng C, Lottenberg S. Magnetic resonance and positron emission tomography imaging of the corpus callosum: size, shape and metabolic rate in unipolar depression. *J Affect Disord*. 1993;28(1):15-25.
48. Lesser IM, Mena I, Boone KB, Miller BL, Mehlinger CM, Wohl M. Reduction of cerebral blood flow in older depressed patients. *Arch Gen Psychiatry*. 1994;51(9):677-686.
49. Miller DS, Kumar A, Yousem DM, Gottlieb GL. MRI high-intensity signals in late-life depression and Alzheimer's disease: a comparison of subjects without major vascular risk factors. *Am J Geriatr Psychiatry*. 1994;2(4):332-337.
50. Dupont RM, Jernigan TL, Heindel W, Butters N, Shafer K, Wilson T, Hesselink J, Gillin JC. Magnetic resonance imaging and mood disorders: localization of white matter and other subcortical abnormalities. *Arch Gen Psychiatry*. 1995;52(9):747-755.
51. Dupont RM, Butters N, Schafer K, Wilson T, Hesselink J, Gillin JC. Diagnostic specificity of focal white matter abnormalities in bipolar and unipolar mood disorder. *Biol Psychiatry*. 1995;38(7):482-486.
52. Lewine RR, Hudgins P, Brown F, Caudle J, Risch SC. Differences in qualitative brain morphology findings in schizophrenia, major depression, bipolar disorder, and normal volunteers. *Schizophr Res*. 1995;15(3):253-259.
53. Wurthmann C, Bogerts B, Falkai P. Brain morphology assessed by computed tomography in patients with geriatric depression, patients with degenerative dementia, and normal control subjects. *Psychiatry Res*. 1995;61(2):103-111.
54. Elkis H, Friedman L, Buckley PF, Lee HS, Lys C, Kaufman B, Meltzer HY. Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. *Psychiatry Res*. 1996;67(2):123-134.
55. Greenwald BS, Kramer-Ginsberg E, Krishnan RR, Ashtari M, Aupperle PM, Patel M. MRI signal hyperintensities in geriatric depression. *Am J Psychiatry*. 1996;153(9):1212-1215.
56. Keshavan MS, Mulsant BH, Sweet RA, Pasternak R, Zubenko GS, Krishnan RR. MRI changes in schizophrenia in late life: a preliminary controlled study. *Psychiatry Res*. 1996;60(2-3):117-123.
57. Lesser IM, Boone KB, Mehlinger CM, Wohl MA, Miller BL, Berman NG. Cognition and white matter hyperintensities in older depressed patients. *Am J Psychiatry*. 1996;153(10):1280-1287.
58. Marchesi C, Silvestrini C, Ponari O, Volpi R, Chiodera P, Coiro V. Unreliability of TRH test but not dexamethasone suppression test as a marker of depression in chronic vasculopathic patients. *Biol Psychiatry*. 1996;40(7):637-641.
59. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. *Nature*. 1997;386(6627):824-827.
60. Kumar A, Miller D, Ewbank D, Yousem D, Newberg A, Samuels S, Cowell P, Gottlieb G. Quantitative anatomic measures and comorbid medical illness in late-life major depression. *Am J Geriatr Psychiatry*. 1997;5(1):15-25.
61. Pantel J, Schröder J, Essig M, Popp D, Dech H, Knopp MV, Schad LR, Eysenbach K, Backenstrass M, Friedlinger M. Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. *J Affect Disord*. 1997;42(1):69-83.
62. Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Fava M, Renshaw PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. *Biol Psychiatry*. 1997;42(2):79-84.
63. Kumar A, Jin Z, Bilker W, Udupa J, Gottlieb G. Late-onset minor and major depression: early evidence for common neuroanatomical substrates detected by using MRI. *Proc Natl Acad Sci U S A*. 1998;95(13):7654-7658.
64. Parashos IA, Tupler LA, Blitchington T, Krishnan KR. Magnetic-resonance morphology in patients with major depression. *Psychiatry Res*. 1998;84(1):7-15.
65. Pillay SS, Renshaw PF, Bonello CM, Lafer BC, Fava M, Yurgelun-Todd D. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. *Psychiatry Res*. 1998;84(2-3):61-74.
66. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. *Neuroreport*. 1998;9(9):2023-2028.
67. Ashtari M, Greenwald BS, Kramer-Ginsberg E, Hu J, Wu H, Patel M, Aupperle P, Pollack S. Hippocampal/amygdala volumes in geriatric depression. *Psychol Med*. 1999;29(3):629-638.
68. Kramer-Ginsberg E, Greenwald BS, Krishnan KR, Christiansen B, Hu J, Ashtari M, Patel M, Pollack S. Neuropsychological functioning and MRI signal hyperintensities in geriatric depression. *Am J Psychiatry*. 1999;156(3):438-444.
69. Lenze E, Cross D, McKeel D, Neuman RJ, Sheline YI. White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. *Am J Psychiatry*. 1999;156(10):1602-1607.
70. Lenze EJ, Sheline YI. Absence of striatal volume differences between depressed subjects with no comorbid medical illness and matched comparison subjects. *Am J Psychiatry*. 1999;156(12):1989-1991.
71. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. *Am J Psychiatry*. 2000;157(1):115-118.
72. Kumar A, Bilker W, Jin Z, Udupa J. Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression. *Neuropsychopharmacology*. 2000;22(3):264-274.
73. Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. *Biol Psychiatry*. 2000;47(12):1087-1090.

74. Caetano SC, Sassi R, Brambilla P, Harenski K, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. MRI study of thalamic volumes in bipolar and unipolar patients and healthy individuals. *Psychiatry Res*. 2001;108(3):161-168.
75. Greenwald BS, Kramer-Ginsberg E, Krishnan KR, Hu J, Ashtari M, Wu H, Aupperle P, Patel M, Pollack S. A controlled study of MRI signal hyperintensities in older depressed patients with and without hypertension. *J Am Geriatr Soc*. 2001;49(9):1218-1225.
76. McIntosh AM, Forrester A, Lawrie SM, Byrne M, Harper A, Kestelman JN, Best JJ, Johnstone EC, Owens DG. A factor model of the functional psychoses and the relationship of factors to clinical variables and brain morphology. *Psychol Med*. 2001;31(1):159-171.
77. Novaretti TM, Marcolin MA, Meira S Jr, Gelás PL, Baudelin CG, Bottino CM. Subcortical hyperintensities on magnetic resonance imaging: a comparison of normal and depressed elderly subjects [in Portuguese]. *Arq Neuropsiquiatr*. 2001;59(3-B):754-760.
78. Rusch BD, Abercrombie HC, Oakes TR, Schaefer SM, Davidson RJ. Hippocampal morphometry in depressed patients and control subjects: relations to anxiety symptoms. *Biol Psychiatry*. 2001;50(12):960-964.
79. Sassi RB, Nicoletti M, Brambilla P, Harenski K, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Decreased pituitary volume in patients with bipolar disorder. *Biol Psychiatry*. 2001;50(4):271-280.
80. Botteron KN, Raichle ME, Drevets WC, Heath AC, Todd RD. Volumetric reduction in left subgenual prefrontal cortex in early onset depression. *Biol Psychiatry*. 2002;51(4):342-344.
81. Brambilla P, Nicoletti MA, Harenski K, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. *Neuropsychopharmacology*. 2002;27(5):792-799.
82. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS. Reduced volume of orbitofrontal cortex in major depression. *Biol Psychiatry*. 2002;51(4):273-279.
83. Frodl T, Meisenzahl E, Zetsche T, Bottlender R, Born C, Groll C, Jäger M, Leinsinger G, Hahn K, Möller HJ. Enlargement of the amygdala in patients with a first episode of major depression. *Biol Psychiatry*. 2002;51(9):708-714.
84. Nolan CL, Moore GJ, Madden R, Farchione T, Bartoi M, Lorch E, Stewart CM, Rosenberg DR. Prefrontal cortical volume in childhood-onset major depression: preliminary findings. *Arch Gen Psychiatry*. 2002;59(2):173-179.
85. Pujol J, Cardoner N, Beniloch L, Urretavizcaya M, Deus J, Losilla JM, Capdevila A, Vallejo J. CSF spaces of the Sylvian fissure region in severe melancholic depression. *Neuroimage*. 2002;15(1):103-106.
86. Salokangas RK, Cannon T, Van Erp T, Ilonen T, Taiminen T, Karlsson H, Laurerma H, Leinonen KM, Wallenius E, Kaljonen A, Sävälähti E, Vilkmann H, Alanen A, Hietala J. Structural magnetic resonance imaging in patients with first-episode schizophrenia, psychotic and severe non-psychotic depression and healthy controls: results of the Schizophrenia and Affective Psychoses (SAP) project. *Br J Psychiatry Suppl*. 2002;43:s58-s65.
87. Steingard RJ, Renshaw PF, Hennen J, Lenox M, Cintron CB, Young AD, Connor DF, Au TH, Yurgelun-Todd DA. Smaller frontal lobe white matter volumes in depressed adolescents. *Biol Psychiatry*. 2002;52(5):413-417.
88. Tupler LA, Krishnan KR, McDonald WM, Dombeck CB, D'Souza S, Steffens DC. Anatomic location and laterality of MRI signal hyperintensities in late-life depression. *J Psychosom Res*. 2002;53(2):665-676.
89. Agid R, Levin T, Gomori JM, Lerer B, Bonne O. T2-weighted image hyperintensities in major depression: focus on the basal ganglia. *Int J Neuropsychopharmacol*. 2003;6(3):215-224.
90. Almeida OP, Burton EJ, Ferrier N, McKeith IG, O'Brien JT. Depression with late onset is associated with right frontal lobe atrophy. *Psychol Med*. 2003;33(4):675-681.
91. Frodl T, Meisenzahl EM, Zetsche T, Born C, Jäger M, Groll C, Bottlender R, Leinsinger G, Möller HJ. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. *Biol Psychiatry*. 2003;53(4):338-344.
92. Lacerda AL, Nicoletti MA, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Anatomical MRI study of basal ganglia in major depressive disorder. *Psychiatry Res*. 2003;124(3):129-140.
93. MacMillan S, Szeszko PR, Moore GJ, Madden R, Lorch E, Ivey J, Banerjee SP, Rosenberg DR. Increased amygdala: hippocampal volume ratios associated with severity of anxiety in pediatric major depression. *J Child Adolesc Psychopharmacol*. 2003;13(1):65-73.
94. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, Nahmias C, Young LT. Course of illness, hippocampal function, and hippocampal volume in major depression. *Proc Natl Acad Sci U S A*. 2003;100(3):1387-1392.
95. Posener JA, Wang L, Price JL, Gado MH, Province MA, Miller MI, Babb CM, Csernansky JG. High-dimensional mapping of the hippocampus in depression. *Am J Psychiatry*. 2003;160(1):83-89.
96. Sassi RB, Brambilla P, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. White matter hyperintensities in bipolar and unipolar patients with relatively mild-to-moderate illness severity. *J Affect Disord*. 2003;77(3):237-245.
97. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. *Am J Psychiatry*. 2003;160(8):1516-1518.
98. Silverstone T, McPherson H, Li Q, Doyle T. Deep white matter hyperintensities in patients with bipolar depression, unipolar depression and age-matched control subjects. *Bipolar Disord*. 2003;5(1):53-57.
99. Baldwin R, Jeffries S, Jackson A, Sutcliffe C, Thacker N, Scott M, Burns A. Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. *Psychol Med*. 2004;34(1):125-136.
100. Ballmaier M, Kumar A, Thompson PM, Narr KL, Lavretsky H, Estanol L, Deluca H, Toga AW. Localizing gray matter deficits in late-onset depression using computational cortical pattern matching methods. *Am J Psychiatry*. 2004;161(11):2091-2099.
101. Ballmaier M, Sowell ER, Thompson PM, Kumar A, Narr KL, Lavretsky H, Welcome SE, DeLuca H, Toga AW. Mapping brain size and cortical gray matter changes in elderly depression. *Biol Psychiatry*. 2004;55(4):382-389.
102. Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. *Psychiatry Res*. 2004;132(2):141-147.
103. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ. Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. *Neuropsychopharmacology*. 2004;29(5):952-959.
104. Janssen J, Hulshoff Pol HE, Lampe IK, Schnack HG, de Leeuw FE, Kahn RS, Heeren TJ. Hippocampal changes and white matter lesions in early-onset depression. *Biol Psychiatry*. 2004;56(11):825-831.
105. Lacerda AL, Keshavan MS, Hardan AY, Yorlisk O, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Soares JC. Anatomic evaluation of the orbitofrontal cortex in major depressive disorder. *Biol Psychiatry*. 2004;55(4):353-358.
106. Lange C, Irie E. Enlarged amygdala volume and reduced hippocampal volume in young women with major depression. *Psychol Med*. 2004;34(6):1059-1064.
107. Lavretsky H, Kurbanyan K, Ballmaier M, Mintz J, Toga A, Kumar A. Sex differences in brain structure in geriatric depression. *Am J Geriatr Psychiatry*. 2004;12(6):653-657.
108. Lloyd AJ, Ferrier IN, Barber R, Gholkar A, Young AH, O'Brien JT. Hippocampal volume change in depression: late- and early-onset illness compared. *Br J Psychiatry*. 2004;184:488-495.
109. MacMaster FP, Kusumakar V. Hippocampal volume in early onset depression. *BMC Med*. 2004;2:2.
110. MacMaster FP, Kusumakar V. MRI study of the pituitary gland in adolescent depression. *J Psychiatr Res*. 2004;38(3):231-236.
111. Supprian T, Reiche W, Schmitz B, Grunwald I, Backens M, Hofmann E, Georg T, Falkai P, Reith W. MRI of the brainstem in patients with major depression, bipolar affective disorder and normal controls. *Psychiatry Res*. 2004;131(3):269-276.
112. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. *Biol Psychiatry*. 2004;56(2):101-112.
113. Xia J, Chen J, Zhou Y, Zhang J, Yang B, Xia L, Wang C. Volumetric MRI analysis of the amygdala and hippocampus in subjects with major depression. *J Huazhong Univ Sci Technol Med Sci*. 2004;24(5):500-502, 506.
114. Chen CS, Tsai JC, Tsang HY, Kuo YT, Lin HF, Chiang IC, Devanand DP. Homocysteine levels, MTHFR C677T genotype, and MRI hyperintensities in late-onset major depressive disorder. *Am J Geriatr Psychiatry*. 2005;13(10):869-875.
115. Coryell W, Nopoulos P, Drevets W, Wilson T, Andreasen NC. Subgenual prefrontal cortex volumes in major depressive disorder and schizophrenia: diagnostic specificity and prognostic implications. *Am J Psychiatry*. 2005;162(9):1706-1712.
116. Hickie I, Naismith S, Ward PB, Turner K, Scott E, Mitchell P, Wilhelm K, Parker G. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. *Br J Psychiatry*. 2005;186:197-202.
117. Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (part I). *Psychiatry Res*. 2005;140(3):291-299.
118. Lacerda AL, Brambilla P, Sassi RB, Nicoletti MA, Mallinger AG, Frank E, Kupfer

- DJ, Keshavan MS, Soares JC. Anatomical MRI study of corpus callosum in unipolar depression. *J Psychiatr Res*. 2005;39(4):347-354.
119. Lavretsky H, Roybal DJ, Ballmaier M, Toga AW, Kumar A. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. *J Clin Psychiatry*. 2005;66(8):964-967.
 120. Lin HF, Kuo YT, Chiang IC, Chen HM, Chen CS. Structural abnormality on brain magnetic resonance imaging in late-onset major depressive disorder. *Kaohsiung J Med Sci*. 2005;21(9):405-411.
 121. Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression. *Biol Psychiatry*. 2005;57(1):21-26.
 122. Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK, Krishnan KR. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. *Arch Gen Psychiatry*. 2005;62(5):537-544.
 123. Caetano SC, Kaur S, Brambilla P, Nicoletti M, Hatch JP, Sassi RB, Mallinger AG, Keshavan MS, Kupfer DJ, Frank E, Soares JC. Smaller cingulate volumes in unipolar depressed patients. *Biol Psychiatry*. 2006;59(8):702-706.
 124. Frodl T, Schaub A, Banac S, Charypar M, Jäger M, Kümmler P, Bottlender R, Zetsche T, Born C, Leinsinger G, Reiser M, Möller HJ, Meisenzahl EM. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. *J Psychiatry Neurosci*. 2006;31(5):316-323.
 125. Hannestad J, Taylor WD, McQuoid DR, Payne ME, Krishnan KR, Steffens DC, Macfall JR. White matter lesion volumes and caudate volumes in late-life depression. *Int J Geriatr Psychiatry*. 2006;21(12):1193-1198.
 126. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, Nierenberg AA, Fava M. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. *Br J Psychiatry*. 2006;188:180-185.
 127. MacMaster FP, Russell A, Mirza Y, Keshavan MS, Taormina SP, Bhandari R, Boyd C, Lynch M, Rose M, Ivey J, Moore GJ, Rosenberg DR. Pituitary volume in treatment-naïve pediatric major depressive disorder. *Biol Psychiatry*. 2006;60(8):862-866.
 128. Naish JH, Baldwin RC, Patankar T, Jeffries S, Burns AS, Taylor CJ, Waterton JC, Jackson A. Abnormalities of CSF flow patterns in the cerebral aqueduct in treatment-resistant late-life depression: a potential biomarker of microvascular angiopathy. *Magn Reson Med*. 2006;56(3):509-516.
 129. Saylam C, Uçerler H, Kitiş Ö, Ozand E, Gönül AS. Reduced hippocampal volume in drug-free depressed patients. *Surg Radiol Anat*. 2006;28(1):82-87.
 130. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. *Arch Gen Psychiatry*. 2006;63(2):139-149.
 131. Weniger G, Lange C, Irle E. Abnormal size of the amygdala predicts impaired emotional memory in major depressive disorder. *J Affect Disord*. 2006;94(1-3):219-229.
 132. Caetano SC, Fonseca M, Hatch JP, Olvera RL, Nicoletti M, Hunter K, Lafer B, Pliszka SR, Soares JC. Medial temporal lobe abnormalities in pediatric unipolar depression. *Neurosci Lett*. 2007;427(3):142-147.
 133. Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, Heuser I. Hippocampal volume reduction and HPA-system activity in major depression. *J Psychiatr Res*. 2007;41(7):553-560.
 134. Hickie IB, Naismith SL, Ward PB, Scott EM, Mitchell PB, Schofield PR, Scimone A, Wilhelm K, Parker G. Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. *J Affect Disord*. 2007;98(1-2):137-142.
 135. Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. *Am J Geriatr Psychiatry*. 2007;15(5):386-394.
 136. Maller JJ, Daskalakis ZJ, Fitzgerald PB. Hippocampal volumetrics in depression: the importance of the posterior tail. *Hippocampus*. 2007;17(11):1023-1027.
 137. Munn MA, Alexopoulos J, Nishino T, Babb CM, Flake LA, Singer T, Ratnanather JT, Huang H, Todd RD, Miller MI, Botteron KN. Amygdala volume analysis in female twins with major depression. *Biol Psychiatry*. 2007;62(5):415-422.
 138. Taylor WD, MacFall JR, Payne ME, McQuoid DR, Steffens DC, Provenzale JM, Krishnan KR. Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. *Psychol Med*. 2007;37(12):1763-1773.
 139. Andreescu C, Butters MA, Begley A, Rajji T, Wu M, Meltzer CC, Reynolds CF III, Aizenstein H. Gray matter changes in late life depression—a structural MRI analysis. *Neuropsychopharmacology*. 2008;33(11):2566-2572.
 140. Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Haroon E, Pham D, Heinz A, Kumar A. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. *Am J Psychiatry*. 2008;165(2):229-237.
 141. Ballmaier M, Kumar A, Elderkin-Thompson V, Narr KL, Luders E, Thompson PM, Hojatkashani C, Pham D, Heinz A, Toga AW. Mapping callosal morphology in early- and late-onset elderly depression: an index of distinct changes in cortical connectivity. *Neuropsychopharmacology*. 2008;33(7):1528-1536.
 142. Chen HH, Rosenberg DR, MacMaster FP, Easter PC, Caetano SC, Nicoletti M, Hatch JP, Nery FG, Soares JC. Orbitofrontal cortex volumes in medication naïve children with major depressive disorder: a magnetic resonance imaging study. *J Child Adolesc Psychopharmacol*. 2008;18(6):551-556.
 143. Eker C, Ovali GY, Ozan E, Eker OD, Kitis O, Coburn K, Gonul AS. No pituitary gland volume change in medication-free depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(7):1628-1632.
 144. Elderkin-Thompson V, Ballmaier M, Hellemann G, Pham D, Lavretsky H, Kumar A. Daily functioning and prefrontal brain morphology in healthy and depressed community-dwelling elderly. *Am J Geriatr Psychiatry*. 2008;16(8):633-642.
 145. Elderkin-Thompson V, Hellemann G, Pham D, Kumar A. Prefrontal brain morphology and executive function in healthy and depressed elderly. *Int J Geriatr Psychiatry*. 2009;24(5):459-468.
 146. Frodl T, Jäger M, Born C, Ritter S, Kraft E, Zetsche T, Bottlender R, Leinsinger G, Reiser M, Möller HJ, Meisenzahl E. Anterior cingulate cortex does not differ between patients with major depression and healthy controls, but relatively large anterior cingulate cortex predicts a good clinical course. *Psychiatry Res*. 2008;163(1):76-83.
 147. Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. *Am J Psychiatry*. 2008;165(7):872-880.
 148. Lenze SN, Xiong C, Sheline YI. Childhood adversity predicts earlier onset of major depression but not reduced hippocampal volume. *Psychiatry Res*. 2008;162(1):39-49.
 149. MacMaster FP, Mirza Y, Szeszko PR, Kmiecik LE, Easter PC, Taormina SP, Lynch M, Rose M, Moore GJ, Rosenberg DR. Amygdala and hippocampal volumes in familial early onset major depressive disorder. *Biol Psychiatry*. 2008;63(4):385-390.
 150. Matsuo K, Rosenberg DR, Easter PC, MacMaster FP, Chen HH, Nicoletti M, Caetano SC, Hatch JP, Soares JC. Striatal volume abnormalities in treatment-naïve patients diagnosed with pediatric major depressive disorder. *J Child Adolesc Psychopharmacol*. 2008;18(2):121-131.
 151. Tae WS, Kim SS, Lee KU, Nam EC, Kim KW. Validation of hippocampal volumes measured using a manual method and two automated methods (FreeSurfer and IBASPM) in chronic major depressive disorder. *Neuroradiology*. 2008;59(7):569-581.
 152. Zanetti MV, Schaufelberger MS, de Castro CC, Menezes PR, Sczufca M, McGuire PK, Murray RM, Busatto GF. White-matter hyperintensities in first-episode psychosis. *Br J Psychiatry*. 2008;193(1):25-30.
 153. Bergouignan L, Chupin M, Czechowska Y, Kinkingnéhun S, Lemogne C, Le Bastard G, Lepage M, Garnero L, Colliot O, Fossati P. Can voxel based morphometry, manual segmentation and automated segmentation equally detect hippocampal volume differences in acute depression? *Neuroimage*. 2009;45(1):29-37.
 154. Exner C, Lange C, Irle E. Impaired implicit learning and reduced pre-supplementary motor cortex size in early-onset major depression with melancholic features. *J Affect Disord*. 2009;119(1-3):156-162.
 155. Jessen F, Schuhmacher A, von Widern O, Guttenthaler V, Hofels S, Suliman H, Scheef L, Block W, Urbach H, Maier W, Zobel A. No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression. *Psychiatr Genet*. 2009;19(2):99-101.
 156. Kronenberg G, Tebartz van Elst L, Regen F, Deuschle M, Heuser I, Colla M. Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression. *J Psychiatr Res*. 2009;43(13):1112-1117.
 157. Kronmüller KT, Schröder J, Köhler S, Götz B, Victor D, Unger J, Giesel F, Magnotta V, Mundt C, Essig M, Pantel J. Hippocampal volume in first episode and recurrent depression. *Psychiatry Res*. 2009;174(1):62-66.
 158. Lorenzetti V, Allen NB, Fornito A, Pantelis C, De Plato G, Ang A, Yücel M. Pituitary gland volume in currently depressed and remitted depressed patients. *Psychiatry Res*. 2009;172(1):55-60.
 159. Milne A, MacQueen GM, Yücel K, Soreni N, Hall GB. Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. *Neuroimage*. 2009;47(1):36-41.
 160. Pan CC, McQuoid DR, Taylor WD, Payne ME, Ashley-Koch A, Steffens DC. Association analysis of the COMT/MTHFR genes and geriatric depression: an MRI study of the putamen. *Int J Geriatr Psychiatry*. 2009;24(8):847-855.
 161. Penttilä J, Pailière-Martinot ML, Martinot JL, Ringuenet D, Wessa M, Houenou J, Gallarda T, Bellivier F, Galinowski A, Bruguière P, Pinabel F, Leboyer M, Olié JP, Duchesnay E, Artiges E, Mangin JF, Cachia A. Cortical folding in patients with bipolar disorder or unipolar depression. *J Psychiatry Neurosci*. 2009;34(2):127-135.
 162. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD,

- Iosifescu DV, Rauch SL, Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. *Am J Psychiatry*. 2009;166(6):702-710.
163. Sun J, Maller JJ, Daskalakis ZJ, Furtado CC, Fitzgerald PB. Morphology of the corpus callosum in treatment-resistant schizophrenia and major depression. *Acta Psychiatr Scand*. 2009;120(4):265-273.
 164. Tamburo RJ, Siegle GJ, Stetten GD, Cois CA, Butters MA, Reynolds CF III, Aizenstein HJ. Amygdalae morphometry in late-life depression. *Int J Geriatr Psychiatry*. 2009;24(8):837-846.
 165. van Eijndhoven P, van Wingen G, van Oijen K, Rijpkema M, Goraj B, Jan Verkes R, Oude Voshaar R, Fernández G, Buitelaar J, Tendolcar I. Amygdala volume marks the acute state in the early course of depression. *Biol Psychiatry*. 2009;65(9):812-818.
 166. Walterfang M, Yücel M, Barton S, Reutens DC, Wood AG, Chen J, Lorenzetti V, Velakoulis D, Pantelis C, Allen NB. Corpus callosum size and shape in individuals with current and past depression. *J Affect Disord*. 2009;115(3):411-420.
 167. Kaymak SU, Demir B, Senturk S, Tatar I, Aldur MM, Ulug B. Hippocampus, glucocorticoids and neurocognitive functions in patients with first-episode major depressive disorders. *Eur Arch Psychiatry Clin Neurosci*. 2010;260(3):217-223.
 168. Köhler S, Thomas AJ, Lloyd A, Barber R, Almeida OP, O'Brien JT. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. *Br J Psychiatry*. 2010;196(2):143-149.
 169. Lorenzetti V, Allen NB, Whittle S, Yücel M. Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. *J Affect Disord*. 2010;120(1-3):112-119.
 170. Meisenzahl EM, Seifert D, Bottlender R, Teipel S, Zetsche T, Jäger M, Koutsouleris N, Schmitt G, Scheuerecker J, Bürgermeister B, Hampel H, Rupprecht T, Born C, Reiser M, Möller HJ, Frodl T. Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. *Eur Arch Psychiatry Clin Neurosci*. 2010;260(2):127-137.
 171. Weber K, Giannakopoulos P, Delaloye C, de Bilbao F, Moy G, Moussa A, Rubio MM, Ebging K, Meuli R, Lazeyras F, Meiler-Mitelu C, Herrmann FR, Gold G, Canuto A. Volumetric MRI changes, cognition and personality traits in old age depression. *J Affect Disord*. 2010;124(3):273-282.
 172. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Roentgenol*. 1987;149(2):351-356.
 173. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. *J Neurol Sci*. 1993;114(1):7-12.
 174. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. *Am J Psychiatry*. 2004;161(4):598-607.
 175. Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. *J Neurosci*. 1990;10(9):2897-2902.
 176. Rubin RT, Phillips JJ, McCracken JT, Sadow TF. Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. *Biol Psychiatry*. 1996;40(2):89-97.
 177. Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. *Psychiatry Res*. 1987;21(3):189-197.
 178. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression: a computed tomographic study. *Arch Gen Psychiatry*. 1992;49(5):384-387.
 179. Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. *Mol Psychiatry*. 2000;5(3):262-269.
 180. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci*. 2000;20(24):9104-9110.
 181. Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. *Neuropsychopharmacology*. 2009;34(11):2376-2389.
 182. Pizzagalli DA, Oakes TR, Fox AS, Chung MK, Larson CL, Abercrombie HC, Schaefer SM, Bencs RM, Davidson RJ. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. *Mol Psychiatry*. 2004;9(4):325, 393-405.
 183. Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. *Acta Psychiatr Scand*. 2000;101(1):11-20.
 184. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dillej G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biol Psychiatry*. 1999;45(9):1085-1098.
 185. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. *J Neurosci*. 2001;21(16):RC159 <http://www.jneurosci.org/cgi/content/full/5472>. Accessed January 11, 2010.
 186. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. "Vascular depression" hypothesis. *Arch Gen Psychiatry*. 1997;54(10):915-922.
 187. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. *J Neurol Neurosurg Psychiatry*. 2008;79(6):619-624.
 188. Coffey CE, Wilkinson WE, Weiner RD, Parashos IA, Djang WT, Webb MC, Figiel GS, Spritzer CE. Quantitative cerebral anatomy in depression: a controlled magnetic resonance imaging study. *Arch Gen Psychiatry*. 1993;50(1):7-16.
 189. Iidaka T, Nakajima T, Kawamoto K, Fukuda H, Suzuki Y, Maehara T, Shiraishi H. Signal hyperintensities on brain magnetic resonance imaging in elderly depressed patients. *Eur Neurol*. 1996;36(5):293-299.
 190. O'Brien JT, Ames D. White matter lesions in depression and Alzheimer's disease [letter]. *Br J Psychiatry*. 1996;169(5):671.
 191. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression: controlled magnetic resonance imaging study. *Br J Psychiatry*. 1998;172:527-532.
 192. Bell-McGinty S, Butters MA, Meltzer CC, Greer PJ, Reynolds CF III, Becker JT. Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration. *Am J Psychiatry*. 2002;159(8):1424-1427.
 193. Vasic N, Walter H, Höse A, Wolf RC. Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. *J Affect Disord*. 2008;109(1-2):107-116.
 194. Wagner G, Koch K, Schachtzabel C, Reichenbach JR, Sauer H, Schlösser RG. Enhanced rostral anterior cingulate cortex activation during cognitive control is related to orbitofrontal volume reduction in unipolar depression. *J Psychiatry Neurosci*. 2008;33(3):199-208.
 195. Frodl T, Koutsouleris N, Bottlender R, Born C, Jäger M, Mörgenthaler M, Scheuerecker J, Zill P, Baghai T, Schüle C, Rupprecht R, Bondy B, Reiser M, Möller HJ, Meisenzahl EM. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. *Mol Psychiatry*. 2008;13(12):1093-1101.
 196. Egger K, Schocke M, Weiss E, Auffinger S, Esterhammer R, Goebel G, Walch T, Mechtcheriakov S, Marksteiner J. Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. *Psychiatry Res*. 2008;164(3):237-244.
 197. Zou K, Deng W, Li T, Zhang B, Jiang L, Huang C, Sun X, Sun X. Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. *Biol Psychiatry*. 2010;67(2):186-188.
 198. Yuan Y, Zhu W, Zhang Z, Bai F, Yu H, Shi Y, Qian Y, Liu W, Jiang T, You J, Liu Z. Regional gray matter changes are associated with cognitive deficits in remitted geriatric depression: an optimized voxel-based morphometry study. *Biol Psychiatry*. 2008;64(6):541-544.
 199. Leung KK, Lee TM, Wong MM, Li LS, Yip PS, Khong PL. Neural correlates of attention biases of people with major depressive disorder: a voxel-based morphometric study. *Psychol Med*. 2009;39(7):1097-1106.
 200. Tang Y, Wang F, Xie G, Liu J, Li L, Su L, Liu Y, Hu X, He Z, Blumberg HP. Reduced ventral anterior cingulate and amygdala volumes in medication-naïve females with major depressive disorder: a voxel-based morphometric magnetic resonance imaging study. *Psychiatry Res*. 2007;156(1):83-86.
 201. Mak AK, Wong MM, Han SH, Lee TM. Gray matter reduction associated with emotion regulation in female outpatients with major depressive disorder: a voxel-based morphometry study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(7):1184-1190.
 202. Mahon K, Burdick KE, Szeszko PR. A role for white matter abnormalities in the pathophysiology of bipolar disorder. *Neurosci Biobehav Rev*. 2010;34(4):533-554.
 203. Craddock N, Jones I. Genetics of bipolar disorder. *J Med Genet*. 1999;36(8):585-594.
 204. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry*. 2000;157(10):1552-1562.
 205. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. *Lancet*. 2000;356(9237):1241-1242.
 206. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbrot M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. *Biol Psychiatry*. 2007;62(1):7-16.
 207. Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. *J Affect Disord*. 2005;84(2-3):149-157.